%0 Generic
%A Gebhart, G.
%A Keyaerts, M.
%A Guiot, T.
%A Flamen, P.
%A Ruiz Borrego, M.
%A Stradella, A.
%A Bermejo De Las Heras, B.
%A Escriva de Romani, S.
%A Calvo-Martinez, L.
%A Ribelles Entrena, N.
%A Martinez, N.
%A Albacar Miro, C. R.
%A Colleoni, M. A.
%A Atienza de Frutos, M.
%A Sampayo-Cordero, M.
%A Cortes, J.
%A Perez Garcia, J. M.
%A Llombart Cussac, A.
%T Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
%D 2022
%@ 0923-7534
%U http://hdl.handle.net/10668/21902
%~